Ultrapotent, Nanoparticle COVID-19 Vaccine with University of Washington Roots Gets $173M for Human Trials

An ultrapotent, second-generation COVID-19 vaccine candidate developed by the University of Washington Medicine’s Institute for Protein Design and South Korea-based SK bioscience received $173.4 million in funding for phase 3 clinical trials. The vaccine, which triggered powerful and lasting immune responses in preclinical trials, employs a nanoparticle technology that was created at the UW institute. If proven effective, the doses will be available to COVAX for equitable worldwide distribution.